FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313308059> ?p ?o ?g. }

• W4313308059 endingPage "15" @default.
• W4313308059 startingPage "15" @default.
• W4313308059 abstract "Background: Sertraline is commonly prescribed to children for the treatment of anxiety and major depressive disorder and is metabolized in part by CYP2C19. While dosing recommendations based on CYP2C19 genotype exist, there is sparse data in children on the relationship between sertraline concentrations and CYP2C19 genotype. Additionally, although rarely utilized in the United States, therapeutic drug monitoring can also help to guide dosing. The primary objective of this pilot study was to compare sertraline concentrations with CYP2C19 genotype. Secondary objectives included exploring the feasibility of using pharmacogenetic testing and therapeutic drug monitoring in a residential treatment center for children and adolescents. Methods: This study was a prospective, open-label study of children prescribed sertraline being treated at a residential treatment center for children and adolescents. Individuals were included if they were < 18 years of age, taking sertraline for at least 2 weeks allowing them to reach steady-state concentrations, being treated through the residential treatment program, and able to understand and speak English. Results: A total of 20 participants (80% female) completed all study procedures, including pharmacogenetic testing and therapeutic drug monitoring, with an average age of 15.4 years (range: 9-17 years). Forty percent (n=8) of participants had a diagnosis of Generalized Anxiety Disorder, while 30% (n=6) had a diagnosis of Major Depressive Disorder. Overall, average sertraline and desmethylsertraline concentrations were 21.1 ng/ml (range: 1-78 ng/ml) and 52.4 ng/ml (range: 1-258 n/ml). Based on CYP2C19 genotypes, 60% (n=12) were normal metabolizers, 10% (n=2) were intermediate metabolizers, and 30% (n=6) were rapid metabolizers. Daily sertraline dose (mg/day) accounted for a significant amount of the observed variability in sertraline (p<0.0001; r2=0.62) and desmethylsertraline concentrations (p<0.001; r2=0.45). When comparing weight-based dosing by sertraline and desmethylsertraline concentrations, sertraline daily dose by weight (mg/kg/day) also accounted for a significant amount of the observed variability in sertraline (p<0.0001; r2=0.60) and desmethylsertraline (p<0.0001; r2=0.59) concentrations. Average daily and weight-based doses for CYP2C19 intermediate, normal, and rapid metabolizers were 75 mg/day, 87.5 mg/day, and 79.2 mg/day and 1.5 mg/kg/day, 1.3 mg/kg/day, and 1.1 mg/kg/day, though these were not significantly different. Conclusion: This small, pilot study showed sertraline dose to be significantly associated with sertraline and desmethylsertraline concentrations. No differences were noted between CYP2C19 metabolizer groups, likely due to the limited sample size. These results also suggest that ordering pharmacogenetic testing and therapeutic drug monitoring in the setting of a child and adolescent residential treatment center is feasible." @default.
• W4313308059 created "2023-01-06" @default.
• W4313308059 creator A5031158609 @default.
• W4313308059 creator A5046278861 @default.
• W4313308059 creator A5089104309 @default.
• W4313308059 date "2022-12-15" @default.
• W4313308059 modified "2023-09-27" @default.
• W4313308059 title "Pharmacogenetic Testing and Therapeutic Drug Monitoring Of Sertraline at a Residential Treatment Center for Children and Adolescents: A Pilot Study" @default.
• W4313308059 cites W2063180688 @default.
• W4313308059 cites W2089629782 @default.
• W4313308059 cites W2131873172 @default.
• W4313308059 cites W2159834407 @default.
• W4313308059 cites W2161620765 @default.
• W4313308059 cites W2169228559 @default.
• W4313308059 cites W2169568318 @default.
• W4313308059 cites W2170495663 @default.
• W4313308059 cites W2460689009 @default.
• W4313308059 cites W2507653617 @default.
• W4313308059 cites W2753966476 @default.
• W4313308059 cites W2792944991 @default.
• W4313308059 cites W2803393726 @default.
• W4313308059 cites W2884641336 @default.
• W4313308059 cites W2917080169 @default.
• W4313308059 cites W2919064206 @default.
• W4313308059 cites W2937447539 @default.
• W4313308059 cites W2944039373 @default.
• W4313308059 cites W2970080281 @default.
• W4313308059 cites W2976967554 @default.
• W4313308059 cites W2981877456 @default.
• W4313308059 cites W2996417030 @default.
• W4313308059 cites W3081436993 @default.
• W4313308059 cites W3111096649 @default.
• W4313308059 cites W3194258577 @default.
• W4313308059 doi "https://doi.org/10.24926/iip.v13i4.5035" @default.
• W4313308059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37305603" @default.
• W4313308059 hasPublicationYear "2022" @default.
• W4313308059 type Work @default.
• W4313308059 citedByCount "1" @default.
• W4313308059 countsByYear W43133080592023 @default.
• W4313308059 crossrefType "journal-article" @default.
• W4313308059 hasAuthorship W4313308059A5031158609 @default.
• W4313308059 hasAuthorship W4313308059A5046278861 @default.
• W4313308059 hasAuthorship W4313308059A5089104309 @default.
• W4313308059 hasBestOaLocation W43133080591 @default.
• W4313308059 hasConcept C104317684 @default.
• W4313308059 hasConcept C118552586 @default.
• W4313308059 hasConcept C126322002 @default.
• W4313308059 hasConcept C135763542 @default.
• W4313308059 hasConcept C140840227 @default.
• W4313308059 hasConcept C185592680 @default.
• W4313308059 hasConcept C2777288759 @default.
• W4313308059 hasConcept C2777669559 @default.
• W4313308059 hasConcept C2779177272 @default.
• W4313308059 hasConcept C2780035454 @default.
• W4313308059 hasConcept C2780051608 @default.
• W4313308059 hasConcept C2780272996 @default.
• W4313308059 hasConcept C2780733359 @default.
• W4313308059 hasConcept C526171541 @default.
• W4313308059 hasConcept C55493867 @default.
• W4313308059 hasConcept C55775858 @default.
• W4313308059 hasConcept C558461103 @default.
• W4313308059 hasConcept C62231903 @default.
• W4313308059 hasConcept C71924100 @default.
• W4313308059 hasConcept C98274493 @default.
• W4313308059 hasConceptScore W4313308059C104317684 @default.
• W4313308059 hasConceptScore W4313308059C118552586 @default.
• W4313308059 hasConceptScore W4313308059C126322002 @default.
• W4313308059 hasConceptScore W4313308059C135763542 @default.
• W4313308059 hasConceptScore W4313308059C140840227 @default.
• W4313308059 hasConceptScore W4313308059C185592680 @default.
• W4313308059 hasConceptScore W4313308059C2777288759 @default.
• W4313308059 hasConceptScore W4313308059C2777669559 @default.
• W4313308059 hasConceptScore W4313308059C2779177272 @default.
• W4313308059 hasConceptScore W4313308059C2780035454 @default.
• W4313308059 hasConceptScore W4313308059C2780051608 @default.
• W4313308059 hasConceptScore W4313308059C2780272996 @default.
• W4313308059 hasConceptScore W4313308059C2780733359 @default.
• W4313308059 hasConceptScore W4313308059C526171541 @default.
• W4313308059 hasConceptScore W4313308059C55493867 @default.
• W4313308059 hasConceptScore W4313308059C55775858 @default.
• W4313308059 hasConceptScore W4313308059C558461103 @default.
• W4313308059 hasConceptScore W4313308059C62231903 @default.
• W4313308059 hasConceptScore W4313308059C71924100 @default.
• W4313308059 hasConceptScore W4313308059C98274493 @default.
• W4313308059 hasIssue "4" @default.
• W4313308059 hasLocation W43133080591 @default.
• W4313308059 hasLocation W43133080592 @default.
• W4313308059 hasLocation W43133080593 @default.
• W4313308059 hasOpenAccess W4313308059 @default.
• W4313308059 hasPrimaryLocation W43133080591 @default.
• W4313308059 hasRelatedWork W2032528677 @default.
• W4313308059 hasRelatedWork W2083976782 @default.
• W4313308059 hasRelatedWork W2612709423 @default.
• W4313308059 hasRelatedWork W2770664124 @default.
• W4313308059 hasRelatedWork W2919064206 @default.
• W4313308059 hasRelatedWork W2924256667 @default.
• W4313308059 hasRelatedWork W4285591863 @default.
• W4313308059 hasRelatedWork W4313308059 @default.

• next